2 unchanged sentences
Holders of Record
−Removed: As of January 31, 2024, there were approximately 76 stockholders of record of our common stock, although we believe that there are a significantly larger number of beneficial owners of our common stock.
+Added: As of February 28, 2025, there were approximately 85 stockholders of record of our common stock, although we believe that there are a significantly larger number of beneficial owners of our common stock.
Dividend Policy
1 unchanged sentence
We intend to retain earnings for use in the operation and expansion of our business.
+Added: Fiscal 2024 Form 10-K
Performance Graph
−Removed: The performance graph included in this Annual Report on Form 10-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference into any filing of Pacific Biosciences under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
+Added: The performance graph included in this Annual Report on Form 10-K shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated by reference into any filing of Pacific Biosciences under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
The following graph shows a comparison from December 31, 2019 through December 31, 2024 of the cumulative total return for our common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index.
1 unchanged sentence
Data for The Nasdaq Composite Index and the Nasdaq Biotechnology Index assume reinvestment of dividends.
−Removed: COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN*
−Removed: Among Pacific Biosciences, Inc, the NASDAQ Composite Index
−Removed: and the NASDAQ Biotechnology Index
−Removed: *$100 invested on 12/31/2018 in stock or index, including reinvestment of dividends.
−Removed: Fiscal year ending December 31.
Recent Sales of Unregistered Securities
−Removed: Other than as previously reported on our Current Reports on Form 8-K filed with the SEC on June 26, 2023 and August 2, 2023, there were no unregistered sales of equity securities by us during 2023.
+Added: Other than as previously reported on our Current Reports on Form 8-K filed with the SEC on November 7, 2024 and November 22, 2024, there were no unregistered sales of equity securities by us during 2024.
+Added: Fiscal 2024 Form 10-K
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.